Patient-derived organoids reveal which breast tumors may resist standard therapies
Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.